Declared Dividend • Jun 08
Dividend reduced to CN¥0.04 Dividend of CN¥0.04 is 84% lower than last year. Ex-date: 9th June 2026 Payment date: 9th June 2026 Dividend yield will be 0.1%, which is lower than the industry average of 2.2%. Reported Earnings • Apr 29
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.05 (down from CN¥0.43 in FY 2024). Revenue: CN¥356.7m (down 8.0% from FY 2024). Net income: CN¥5.62m (down 89% from FY 2024). Profit margin: 1.6% (down from 14% in FY 2024). Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 72%. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Announcement • Apr 29
Caina Technology Co., Ltd., Annual General Meeting, May 22, 2026 Caina Technology Co., Ltd., Annual General Meeting, May 22, 2026, at 15:00 China Standard Time. Location: 1F, No. 23, Huanxi Road, Zhutang Town, Jiangyin, Jiangsu China Announcement • Mar 31
Caina Technology Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Caina Technology Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 7 highly experienced directors. Independent Director Bin Liu was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Dec 31
Caina Technology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026 Caina Technology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026 New Risk • Oct 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 7x earnings per share. Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.1% net profit margin). New Risk • Oct 25
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 110% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 7x earnings per share. Paying a dividend despite having no free cash flows. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.1% net profit margin). Reported Earnings • Oct 25
Third quarter 2025 earnings released: CN¥0.009 loss per share (vs CN¥0.20 profit in 3Q 2024) Third quarter 2025 results: CN¥0.009 loss per share (down from CN¥0.20 profit in 3Q 2024). Revenue: CN¥87.4m (down 11% from 3Q 2024). Net loss: CN¥1.12m (down 105% from profit in 3Q 2024). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Caina Technology Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025 Caina Technology Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025 Announcement • Jul 02
Caina Technology Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Caina Technology Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Declared Dividend • May 25
Dividend reduced to CN¥0.25 Dividend of CN¥0.25 is 38% lower than last year. Ex-date: 30th May 2025 Payment date: 30th May 2025 Dividend yield will be 1.2%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (87% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 103% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • Apr 26
New major risk - Revenue and earnings growth Earnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (10% net profit margin). Announcement • Apr 25
Caina Technology Co., Ltd., Annual General Meeting, May 16, 2025 Caina Technology Co., Ltd., Annual General Meeting, May 16, 2025, at 14:30 China Standard Time. Location: 1F, No. 23, Huanxi Road, Zhutang Town, Jiangyin, Jiangsu China New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Earnings are forecast to decline by an average of 11% per year for the foreseeable future. High level of non-cash earnings (39% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change). Announcement • Mar 31
Caina Technology Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Caina Technology Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 New Risk • Mar 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Earnings are forecast to decline by an average of 11% per year for the foreseeable future. High level of non-cash earnings (39% accrual ratio). New Risk • Feb 05
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 11% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 11% per year for the foreseeable future. High level of non-cash earnings (39% accrual ratio). Announcement • Dec 31
Caina Technology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 Caina Technology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥25.45, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 38% over the past year. New Risk • Nov 10
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (19% net profit margin). Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥19.98, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 48% over the past year. Announcement • Sep 30
Caina Technology Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Caina Technology Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 New Risk • Sep 19
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 9.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 9.4% per year for the foreseeable future. High level of non-cash earnings (44% accrual ratio). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.29 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.068 (down from CN¥0.29 in 2Q 2023). Revenue: CN¥83.8m (down 24% from 2Q 2023). Net income: CN¥8.15m (down 77% from 2Q 2023). Profit margin: 9.7% (down from 32% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Announcement • Jun 29
Caina Technology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Caina Technology Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Declared Dividend • May 16
Dividend of CN¥0.40 announced Shareholders will receive a dividend of CN¥0.40. Ex-date: 21st May 2024 Payment date: 21st May 2024 Dividend yield will be 1.8%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 13% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 92% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 20
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: CN¥0.92 (down from CN¥1.35 in FY 2022). Revenue: CN¥410.5m (down 12% from FY 2022). Net income: CN¥112.6m (down 31% from FY 2022). Profit margin: 27% (down from 35% in FY 2022). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 13%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Announcement • Apr 20
Caina Technology Co., Ltd., Annual General Meeting, May 10, 2024 Caina Technology Co., Ltd., Annual General Meeting, May 10, 2024, at 14:30 China Standard Time. Location: 1F, No. 23, Huanxi Road, Zhutang Town, Jiangyin, Jiangsu China Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥22.48, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 39% over the past year. Announcement • Mar 30
Caina Technology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024 Caina Technology Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024 Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥30.58, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 21% over the past year. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥23.40, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 49% over the past year. Announcement • Dec 29
Caina Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024 Caina Technology Co., Ltd. announced that they will report fiscal year 2023 results on Apr 19, 2024 Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥36.17, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 25x in the Medical Equipment industry in China. Total loss to shareholders of 25% over the past year. Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.28 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.34 (up from CN¥0.28 in 3Q 2022). Revenue: CN¥116.5m (up 13% from 3Q 2022). Net income: CN¥41.4m (up 20% from 3Q 2022). Profit margin: 36% (up from 33% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. New Risk • Oct 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (44% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.4% average weekly change). Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥42.40, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 22x in the Medical Equipment industry in China. Total returns to shareholders of 9.2% over the past year. Reported Earnings • Aug 25
Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.49 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.29 (down from CN¥0.49 in 2Q 2022). Revenue: CN¥110.3m (down 17% from 2Q 2022). Net income: CN¥35.4m (down 41% from 2Q 2022). Profit margin: 32% (down from 46% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Announcement • Jul 18
Caina Technology Co., Ltd. Announces Board Appointments Caina Technology Co., Ltd. held its 2nd Extraordinary General Meeting of 2023 on 14 July 2023, approved the appointment of Zha Lingyun, Cheng Rufa, Hou Peng as non-independent directors. Liu Bin, Wang Shanghu and Xia Liyang as independent directors. Ji Chunxia and Wu Yaqing as non-employee supervisors. Buying Opportunity • Jul 12
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 4.5%. The fair value is estimated to be CN¥47.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has declined by 18%. Revenue is forecast to grow by 144% in 2 years. Earnings is forecast to grow by 113% in the next 2 years. Announcement • Jul 01
Caina Technology Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023 Caina Technology Co., Ltd. announced that they will report first half, 2023 results on Aug 25, 2023 Buying Opportunity • May 16
Now 32% undervalued after recent price drop Over the last 90 days, the stock is down 44%. The fair value is estimated to be CN¥48.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has declined by 18%. Revenue is forecast to grow by 144% in 2 years. Earnings is forecast to grow by 114% in the next 2 years. Valuation Update With 7 Day Price Move • May 16
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥32.75, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 26x in the Medical Equipment industry in China. Total loss to shareholders of 43% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.78 per share. Announcement • May 11
Caina Technology Co., Ltd. Announces Cash Dividend for 2022, Payable on 16 May 2023 Caina Technology Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares) as cash dividend/10 shares (tax included): CNY 4.50000000. Record date is 15 May 2023. Ex-date is 16 May 2023. Payment date is 16 May 2023. Reported Earnings • Apr 12
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥1.76. Revenue: CN¥465.5m (up 5.3% from FY 2021). Net income: CN¥161.9m (up 24% from FY 2021). Profit margin: 35% (up from 30% in FY 2021). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 2.8%. Revenue is forecast to grow 40% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman & GM Jun Lu was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment deteriorated over the past week After last week's 22% share price decline to CN¥51.03, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 24x in the Medical Equipment industry in China. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.49 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.37 (down from CN¥0.49 in 3Q 2021). Revenue: CN¥103.2m (down 15% from 3Q 2021). Net income: CN¥34.5m (flat on 3Q 2021). Profit margin: 33% (up from 29% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥68.26, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 26x in the Medical Equipment industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥31.38 per share. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.64 (vs CN¥0.35 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.64 (up from CN¥0.35 in 2Q 2021). Revenue: CN¥132.6m (up 34% from 2Q 2021). Net income: CN¥60.3m (up 148% from 2Q 2021). Profit margin: 46% (up from 25% in 2Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 62%, compared to a 26% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Aug 17
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥86.14, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 23x in the Medical Equipment industry in China. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.43 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.46 (up from CN¥0.43 in 1Q 2021). Revenue: CN¥141.6m (up 42% from 1Q 2021). Net income: CN¥39.3m (up 28% from 1Q 2021). Profit margin: 28% (down from 31% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 57%, compared to a 25% growth forecast for the industry in China. Announcement • Apr 20
Caina Technology Co., Ltd. Approves the Implementation of Final Cash Dividend, Payable on 25 April 2022 Caina Technology Co., Ltd. approved the implementation of final cash dividend of CNY 3.50000000 per 10 A shares (tax included). Record date is 22 April 2022 with Ex-date on 25 April 2022 and payment date on 25 April 2022. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Net cash dividend per 10 shares after tax: CNY 3.15000000(CNY 3.50000000- CNY 0.35000000). Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥55.11, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 21x in the Medical Equipment industry in China. Announcement • Apr 08
Caina Technology Approves Cash Dividend for 2021 Caina Technology Co., Ltd. at the AGM held on April 1, 2022 approved cash dividend/10 shares (tax included) of CNY 3.50000000 for 2021. Reported Earnings • Mar 11
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: CN¥1.85 (down from CN¥2.05 in FY 2020). Revenue: CN¥442.1m (down 13% from FY 2020). Net income: CN¥130.7m (down 4.6% from FY 2020). Profit margin: 30% (up from 27% in FY 2020). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥78.40, the stock trades at a trailing P/E ratio of 78.4x. Average trailing P/E is 35x in the Medical Equipment industry in China.